Critical Outcome Technologies Inc. Announces Management Change

"On behalf of COTI's Board and entire management team, I wish to thank Dean for his dedication and efforts in helping bring the Company to this stage of development", said Mr. John Drake, Chairman of the Board and CEO of COTI. "Dean's valuable contribution towards our public financing initiative was greatly appreciated. We certainly wish him well in his future endeavours."

COTI has assigned Mr. Gendron's areas of responsibility to its Chief Operating Officer, Mr. J.L. Scott Baker and its Director of Business Development and Marketing, Mr. Michael Barr.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Website: www.criticaloutcome.com